EUVIMEDEUVIMED entdecken
Crossref

Gemcitabine Intravesical Drug-Releasing System in Bacillus Calmette-Guérin–Unresponsive Papillary-Only High-Risk Non–Muscle-Invasive Bladder Cancer: 12-Month Update From SunRISe-1 Cohort 4

Siamak Daneshmand, Michiel S. Van der Heijden, David Cahn, Eugene B. Cone, Laurence Belkoff, Daniel Zainfeld, Won Kim, Shalaka Hampras, Jason Martin, Abhijit Shukla, Katharine Stromberg, Christopher J. Cutie und 10 weitere

JCO Oncology Advances · 2026-10 · 3 (4)

DOI: 10.1200/oa-26-00012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-10. Verfasst von Siamak Daneshmand und 21 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Patients with bacillus Calmette-Guérin (BCG)–unresponsive papillary-only high-risk non–muscle-invasive bladder cancer (HR NMIBC) have limited bladder-sparing treatment options; radical cystectomy (RC) is the standard of care despite significant morbidity and mortality risks. We report efficacy and safety of the gemcitabine intravesical drug-releasing system (gem-iDRS) in patients with BCG-unresponsive papillary-only HR NMIBC enrolled in Cohort 4 of the phase IIb SunRISe-1 study (ClinicalTrials.gov identifier: NCT04640623 ).

Methods

Patients received gem-iDRS every 3 weeks through month 6 and then every 12 weeks through month 24. The primary end point was disease-free survival (DFS).

Results

Fifty-two patients were treated. At clinical cutoff (July 3, 2025), the median follow-up was 15.9 months. The 12-month DFS rate was 76.0% (95% CI, 60.8 to 86.0), with comparable efficacy in high-grade Ta and T1 disease. The 12-month overall survival and RC-free rates were 98.0% (95% CI, 86.6 to 99.7) and 93.8% (95% CI, 81.9 to 97.9), respectively. The progression-free survival at 12 months was 95.6% (95% CI, 83.5 to 98.9) in a post hoc analysis. Grade ≥3 treatment-related adverse events occurred in 13.5% of patients, most commonly bladder pain (3.8%). Patient-reported quality of life remained stable throughout treatment.

Conclusion

Gem-iDRS demonstrated high efficacy, a favorable benefit-risk profile, supporting its investigation as a potential bladder-sparing treatment option for BCG-unresponsive papillary-only HR NMIBC.

Zitieren

APA

Daneshmand, S., Heijden, M. S. V. D., Cahn, D., Cone, E. B., Belkoff, L., Zainfeld, D., Kim, W., Hampras, S., Martin, J., Shukla, A., Stromberg, K., Cutie, C. J., Bertzos, K., Kandori, S., Xylinas, E., Lotan, Y., Mazzarella, B., Kassouf, W., Necchi, A., …, & Jacob, J. M. (2026). Gemcitabine Intravesical Drug-Releasing System in Bacillus Calmette-Guérin–Unresponsive Papillary-Only High-Risk Non–Muscle-Invasive Bladder Cancer: 12-Month Update From SunRISe-1 Cohort 4. JCO Oncology Advances, 3(4). https://doi.org/10.1200/oa-26-00012

Vancouver

Daneshmand S, Heijden MSVD, Cahn D, Cone EB, Belkoff L, Zainfeld D, et al. Gemcitabine Intravesical Drug-Releasing System in Bacillus Calmette-Guérin–Unresponsive Papillary-Only High-Risk Non–Muscle-Invasive Bladder Cancer: 12-Month Update From SunRISe-1 Cohort 4. JCO Oncology Advances. 2026;3(4). doi:10.1200/oa-26-00012

BibTeX
@article{Daneshmand2026,
  author = {Daneshmand, Siamak and Heijden, Michiel S. Van der and Cahn, David and Cone, Eugene B. and Belkoff, Laurence and Zainfeld, Daniel and Kim, Won and Hampras, Shalaka and Martin, Jason and Shukla, Abhijit and Stromberg, Katharine and Cutie, Christopher J. and Bertzos, Kristi and Kandori, Shuya and Xylinas, Evanguelos and Lotan, Yair and Mazzarella, Brian and Kassouf, Wassim and Necchi, Andrea and Pieczonka, Christopher M. and Guerrero-Ramos, Felix and Jacob, Joseph M.},
  title = {Gemcitabine Intravesical Drug-Releasing System in Bacillus Calmette-Guérin–Unresponsive Papillary-Only High-Risk Non–Muscle-Invasive Bladder Cancer: 12-Month Update From SunRISe-1 Cohort 4},
  journal = {JCO Oncology Advances},
  year = {2026},
  volume = {3},
  number = {4},
  doi = {10.1200/oa-26-00012}
}
Kostenlos starten →